Thiabendazole, an orally administered benzimidazole fungicide, possesses repellent and anticancer properties. It is also known to cause developmental malformations and is used for research modeling purposes.[1][2][3][4][5]
体内研究
When administered at a dosage of 50 mg/kg for 27 days, it slows tumor growth in a mouse model using Xenopus.[3]
Additionally, Thiabendazole induces developmental defects in zebrafish through mechanisms involving apoptosis, oxidative stress, and alterations in the PI3K/Akt and MAPK pathways, at concentrations ranging from 0 to 20 mg/L over periods from 0 to 96 hours post-fertilization (hpf).[4]
体外研究
In laboratory studies, Thiabendazole inhibits the proliferation of B16F10 and B16 cells in a manner that is both time and dose-dependent at concentrations ranging from 0 to 500 μM over periods of 24, 48, and 72 hours.[2]
At a concentration of 250 μM for 16 hours, it inhibits angiogenesis in Xenopus embryos and disrupts established vasculature.[3]
Thiabendazole/噻菌灵 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
NZB/NZW F1 female mice
Systemic lupus erythematosus (SLE) model
Intraperitoneal
0.2 mg/kg (intraperitoneal)
Once a week, from 2 to 9 months of age, followed by 2 months without treatment
To evaluate the therapeutic effect of TBZ/DNFB on lupus nephritis in mice. Results showed that TBZ/DNFB significantly reduced glomerular deposition of immunoglobulins and complement components, suppressed proliferative glomerulonephritis, and markedly decreased proteinuria.
搜索
